Skip to main content

First-in-human clinical trials for cancer and blood disorders

This Journal of Hematology & Oncology series calls for clinical studies on novel agents for cancers and blood disorders. Summaries and reviews on first-in-human or first-in-class studies are also welcome.

To submit, please visit the journal's editorial management system.

© Deepak Sethi / Getty Images / iStock.

  1. T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field of cel...

    Authors: Chenggong Li, Fen Zhou, Jing Wang, Qi Chang, Mengyi Du, Wenjing Luo, Yinqiang Zhang, Jia Xu, Lu Tang, Huiwen Jiang, Lin Liu, Haiming Kou, Cong Lu, Danying Liao, Jianghua Wu, Qiuzhe Wei…
    Citation: Journal of Hematology & Oncology 2023 16:5
  2. No fully validated risk-stratification strategies have been established in China where colonoscopies resources are limited. We aimed to develop and validate a fecal immunochemical test (FIT)-based risk-stratif...

    Authors: Shengbing Zhao, Shuling Wang, Peng Pan, Tian Xia, Rundong Wang, Quancai Cai, Xin Chang, Fan Yang, Lun Gu, Zixuan He, Jiayi Wu, Qianqian Meng, Tongchang Wang, Qiwen Fang, Xiaomei Mou, Honggang Yu…
    Citation: Journal of Hematology & Oncology 2022 15:162
  3. The discovery of immune checkpoint inhibitors (ICIs) has now been universally acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of checkpoint molecules: anti-programmed c...

    Authors: Yuchen Wang, Hao Zhang, Chao Liu, Zeyu Wang, Wantao Wu, Nan Zhang, Longbo Zhang, Jason Hu, Peng Luo, Jian Zhang, Zaoqu Liu, Yun Peng, Zhixiong Liu, Lanhua Tang and Quan Cheng
    Citation: Journal of Hematology & Oncology 2022 15:111
  4. Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis. In this study, we evaluated chimeric antigen receptor (CAR) T cell therapy targeting CLL-1 in adults with R/R AML patients. Patie...

    Authors: Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao, Xiaomei Zhang, Fan Li, Danni Xie, Xia Xiong, Jiaxi Wang, Wenyi Lu, Hongkai Zhang and Mingfeng Zhao
    Citation: Journal of Hematology & Oncology 2022 15:88
  5. BCMA-specific chimeric antigen receptor-T cells (CAR-Ts) have exhibited remarkable efficacy in refractory or relapsed multiple myeloma (RRMM); however, primary resistance and relapse exist with single-target i...

    Authors: Heng Mei, Chenggong Li, Huiwen Jiang, Xinying Zhao, Zhiping Huang, Dan Jin, Tao Guo, Haiming Kou, Lin Liu, Lu Tang, Ping Yin, Zhihui Wang, Lisha Ai, Sha Ke, Yimeng Xia, Jun Deng…
    Citation: Journal of Hematology & Oncology 2021 14:161
  6. YY-20394, an oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor, was investigated in a first-in-human study of patients with relapsed or refractory B-cell malignancies. During dose escalation, 25 patie...

    Authors: Bo Jiang, Junyuan Qi, Yuqin Song, Zengjun Li, Meifeng Tu, Lingyan Ping, Zongliang Liu, Hanying Bao, Zusheng Xu and Lugui Qiu
    Citation: Journal of Hematology & Oncology 2021 14:130
  7. The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies.

    Authors: Apostolia-Maria Tsimberidou, Jamie V. Shaw, Dejan Juric, Claire Verschraegen, Amy M. Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers-Lenz, Hui Tian, Wenyuan Xiong, Remigiusz Kaleta and Razelle Kurzrock
    Citation: Journal of Hematology & Oncology 2021 14:127
  8. Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intraveno...

    Authors: Jian Li, Yanhong Deng, Weijie Zhang, Ai-Ping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, David Liu and Lin Shen
    Citation: Journal of Hematology & Oncology 2021 14:95